MindWalk Holdings, a US AI company with a UK office in Bristol, has appointed Thomas W. Lynch, Ph.D., as Chief Business Officer (CBO).
Dr. Lynch is an experienced sector manager with over two decades of experience concentrated at the intersection of biotechnology and software creativity. Dr. Lynch has a strong history of expanding global commercial organisations, introducing impactful products, and encouraging market adoption of sophisticated software and data platforms. His career covers technical sales, customer services, and business development, where he has consistently delivered growth by merging thorough scientific understanding with focused commercial execution.
Dr. Jennifer Bath, CEO of MindWalk, commented: “Tom’s combination of biotech depth and software commercialization expertise directly supports MindWalk’s next path of growth. As we expand the reach of our HYFT-powered Deep Data platform across pharma and biotech markets worldwide, Tom’s leadership in scaling global teams and forging strategic partnerships will be instrumental in creating long-term shareholder value.”
Dr. Lynch concluded: “MindWalk sits at the frontier of AI-native data intelligence in life sciences. I am excited to help accelerate the Company’s growth trajectory by translating its powerful technology into solutions that drive measurable value for customers, partners, and investors alike.”
MindWalk’s appointment of Dr. Lynch marks a further step in implementing its commercial strategy to broaden acceptance of its Bio-Native AI platform, positioning the company to capture a growing share of the multibillion-pound life sciences data analytics market.
Powered by patented HYFT technology and the LensAI platform, MindWalk integrates sequence, structure, function, and literature into a single computational language and completes the process with an integrated, full-stack wet lab.
Image source: LinkedIn
